Media
Corgentech to Present at 23rd Annual JPMorgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan 05, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 23rd Annual JPMorgan Healthcare Conference on Wednesday, January 12, 2005, at 11:00 a.m. Pacific Standard Time in San Francisco, CA.
To access the live webcast or the subsequent archived recording, log on to www.corgentech.com and go to the Investors page, and click on Webcasts. Please connect to Corgentech's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Corgentech
Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. The company is creating a pipeline of novel therapeutics based on its proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease and cancer. For more information on the company and its technology, visit www.corgentech.com.
SOURCE Corgentech Inc.
Jennifer Cook Williams, Senior Director, Investor Relations, or Corgentech Inc., +1-650-624-9600, or [email protected]
http://www.prnewswire.com
Copyright (C) 2005 PR Newswire. All rights reserved.
News Provided by COMTEX
